Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04060108 · ClinicalTrials.gov registry record
Stanford Regulating Circuits of the Brain Study - MDMA
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 22
- Enrollment target
NCT04060108: Completed study, sponsored by Stanford University.
NCT04060108 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04060108 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 22 participants
- Enrollment target
Study Summary
This study is a biomarker study designed to characterize how human neural circuits and behaviors are modified during altered states induced by MDMA.
Primary Outcome
For the non-conscious task, participants are shown a series of faces, presented in pairs. The first face in each pair is presented for only a fraction of a second and may be hard to see. Participants press a button every time they see a face. For the conscious task, participants do the same thing same but with a new set of faces.
Interventions
- DRUG MDMA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2021-11-02 |
| Est. Completion | 2024-01-01 |
What the finished NCT04060108 record still lists
NCT04060108 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 22 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which MDMA is the first listed.
NCT04060108 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04060108 about?
NCT04060108 is a clinical study titled "Stanford Regulating Circuits of the Brain Study - MDMA". This study is a biomarker study designed to characterize how human neural circuits and behaviors are modified during altered states induced by MDMA.
What is the current status of trial NCT04060108?
This trial is currently completed. The enrollment target is 22 participants. The study started on 2021-11-02. Estimated completion is 2024-01-01.
What interventions are being tested in trial NCT04060108?
The interventions under investigation include: MDMA (DRUG).
Who is sponsoring clinical trial NCT04060108?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI